Chiquette E, Amato M G, Bussey H I
Clinical Pharmacy Programs at the University of Texas at Austin, USA.
Arch Intern Med. 1998;158(15):1641-7. doi: 10.1001/archinte.158.15.1641.
The outcomes of an inception cohort of patients seen at an anticoagulation clinic (AC) were published previously. The temporary closure of this clinic allowed the evaluation of 2 more inception cohorts: usual medical care and an AC.
To compare newly anticoagulated patients who were treated with usual medical care with those treated at an AC for patient characteristics, anticoagulation control, bleeding and thromboembolic events, and differences in costs for hospitalizations and emergency department visits.
Rates are expressed as percentage per patient-year. Patients treated at an AC who received lower-range anticoagulation had fewer international normalized ratios greater than 5.0 (7.0% vs 14.7%), spent more time in range (40.0% vs 37.0%), and spent less time at an international normalized ratio greater than 5 (3.5% vs 9.8%). Patients treated at an AC who received higher-range anticoagulation had more international normalized ratios within range (50.4% vs 35.0%), had fewer international normalized ratios less than 2.0 (13.0% vs 23.8%), and spent more time within range (64.0% vs 51.0%). The AC group had lower rates (expressed as percentage per patient-year) of significant bleeding (8.1% vs 35.0%), major to fatal bleeding (1.6% vs 3.9%), and thromboembolic events (3.3% vs 11.8%); the AC group also demonstrated a trend toward a lower mortality rate (0% vs 2.9%; P= .09). Significantly lower annual rates of warfarin sodium-related hospitalizations (5% vs 19%) and emergency department visits (6% vs 22%) reduced annual health care costs by $132086 per 100 patients. Additionally, a lower rate of warfarin-unrelated emergency department visits (46.8% vs 168.0%) produced an additional annual savings in health care costs of $29 72 per 100 patients.
A clinical pharmacist-run AC improved anticoagulation control, reduced bleeding and thromboembolic event rates, and saved $162058 per 100 patients annually in reduced hospitalizations and emergency department visits.
抗凝门诊(AC)起始队列患者的治疗结果此前已发表。该门诊的临时关闭使得能够评估另外两个起始队列:常规医疗护理和抗凝门诊。
比较接受常规医疗护理的新抗凝患者与在抗凝门诊接受治疗的患者在患者特征、抗凝控制、出血和血栓栓塞事件以及住院和急诊就诊费用方面的差异。
发生率以每位患者每年的百分比表示。在抗凝门诊接受较低剂量抗凝治疗的患者国际标准化比值大于5.0的情况较少(7.0%对14.7%),处于目标范围的时间更多(40.0%对37.0%),国际标准化比值大于5的时间更少(3.5%对9.8%)。在抗凝门诊接受较高剂量抗凝治疗的患者国际标准化比值在目标范围内的情况更多(50.4%对35.0%),国际标准化比值小于2.0的情况较少(13.0%对23.8%),处于目标范围的时间更多(64.0%对51.0%)。抗凝门诊组严重出血(8.1%对35.0%)、重大至致命出血(1.6%对3.9%)和血栓栓塞事件(3.3%对11.8%)的发生率较低(以每位患者每年的百分比表示);抗凝门诊组死亡率也有降低趋势(0%对2.9%;P = 0.09)。华法林钠相关住院(5%对19%)和急诊就诊(6%对22%)的年发生率显著降低,使每100名患者每年的医疗保健费用减少132086美元。此外,华法林无关的急诊就诊率较低(46.8%对168.0%),使每100名患者每年的医疗保健费用额外节省2972美元。
由临床药剂师管理的抗凝门诊改善了抗凝控制,降低了出血和血栓栓塞事件发生率,并且通过减少住院和急诊就诊,每100名患者每年节省162058美元。